Thor Medical (TRMED.OL)

Executive Summary

Thor Medical ASA is a Norwegian radiopharmaceutical company positioned to become a leading supplier of alpha-emitting isotopes for targeted cancer therapy. Its proprietary, environmentally friendly process extracts Radium-224 and Lead-212 from natural thorium-232, addressing the critical shortage of alpha emitters needed for next-generation radionuclide therapies. The company currently operates a pilot facility and is actively scaling up commercial production to meet growing demand from pharmaceutical partners. With a strong focus on quality and sustainability, Thor Medical aims to secure a significant share of the rapidly expanding radiopharmaceutical market. As Thor Medical transitions from pilot to commercial scale, its near-term success hinges on executing its production scale-up and forging strategic partnerships with drug developers. The company's isotopes, particularly Lead-212 with favorable half-life and decay properties, are well-suited for emerging targeted alpha therapies. However, as a pre-commercial entity, Thor Medical faces typical scale-up risks and regulatory hurdles. If successful, it could become a critical enabler of alpha therapy treatments, offering a reliable and scalable supply chain for the oncology community.

Upcoming Catalysts (preview)

• Q4 2026Completion of commercial-scale production facility65% success
• Q2 2027First commercial supply agreement with a radiopharma partner55% success
• Q2 2026Update on preclinical or early clinical data for Lead-212 programs40% success